Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D) [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial of a personalized antisense oligonucleotide for Charcot-Marie-Tooth disease Type 2D caused by GARS1 mutation; enrollment is by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease Type 2d

Snippet

Sponsor: n-Lorem Foundation | Conditions: Charcot-Marie-Tooth Disease Type 2D | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION